Austrianova, also known as SGAustria, a leading provider of cell biological products and services, has unveiled plans to expand its facilities in Thailand and Singapore. The company has increased its capacity at its facility in Thailand Science Park in Pathumthani, metro Bangkok, where it has production suites and R&D labs. The facility focuses on the Cell-in-a-Box® cell encapsulation technology platform, which is used to protect human and animal cells from immune rejection and clearance when implanted in the body, as well as for long-term storage in the frozen state. Austrianova Thailand produces cell banks and other cell therapy-related products in addition to working with partners and clients who use the technology.
Austrianova Singapore, on the other hand, focuses on the Bac-in-a-Box® encapsulation technology, which is used to protect bacteria and yeast cells from the sterilizing effects of stomach acid, allowing them to be stored at room temperature without significant loss in viability. The technology is used in a variety of applications, including probiotics and modification of the microbiome by selective and efficient delivery of bacteria to treat dysbiosis of the gastric tract and skin health. Austrianova Singapore is also preparing to expand its facility for pilot-scale production of Bac-in-a-Box®-based bacterial and yeast products.
The expansion of Austrianova’s facilities in Thailand and Singapore will enable the company to increase its capacity for the production of its innovative cell and bacteria encapsulation technologies. These technologies have broad applications in cell therapy and biotechnology, and the expansion will allow Austrianova to better serve its customers in the region. The expansion also reflects the company’s commitment to advancing the field of cell biology and biotechnology and improving human health.